Q2 2026 saw double-digit sales growth, improved profitability, and strong free cash flow, driven by innovation in Prosthetics & Neuro Orthotics and successful strategic initiatives. Guidance for 2026 was narrowed, with continued focus on R&D, sustainability, and expansion in emerging markets.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.